Does GLP-1 Treatment Help Obesity? The Complete Treatment Guide

Last reviewed: June 15, 2026

Last updated: June 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes — and the evidence supporting that answer is unusually strong for obesity pharmacotherapy. Two large randomized programs anchor it. In the pivotal 68-week Wegovy trial in adults with obesity or overweight with a comorbidity, semaglutide 2.4 mg produced a mean body weight change of -14.9% versus -2.4% with placebo, per the Wegovy prescribing information. In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity or overweight without diabetes, tirzepatide produced mean weight changes of -15.0%, -19.5% and -20.9% across three doses versus -3.1% with placebo. What the evidence also shows is that these are treatments for a chronic condition, not a finite course.

What "Helps" Means in the Trial Record

The Wegovy label reports three 68-week randomized, double-blind, placebo-controlled trials plus a withdrawal trial and additional 72-week trials. In the trial in adults without diabetes, 83.5% of participants on semaglutide lost at least 5% of body weight versus 31.1% on placebo, and 47.9% lost at least 15% versus 4.8%.

In the parallel trial in adults with type 2 diabetes and a BMI of at least 27, the mean change was -9.6% versus -3.4%. The smaller effect in diabetes is a consistent finding across this drug class and is one reason a prescriber's assessment matters more than a headline number.

The Mechanism, Stated Carefully

GLP-1 receptor agonists act on receptors involved in glucose-dependent insulin secretion, gastric emptying and appetite regulation. The clinical consequence most patients notice is reduced energy intake. Tirzepatide adds agonism at the glucose-dependent insulinotropic polypeptide receptor, a second incretin pathway.

It is worth resisting the tidier version of this story. Describing these drugs as simply "controlling hunger signals" understates the metabolic effects captured in the trials, including the glycemic and cardiovascular outcomes that support separate indications on these labels.

Obesity Is Being Treated as Chronic Because It Behaves That Way

The Wegovy label reports a withdrawal trial in which participants ran in on semaglutide for 20 weeks and were then randomized to continue or switch to placebo. From randomization at week 20 to week 68, those who continued lost a further 7.9% while those switched to placebo regained 6.9%, a difference of 14.8 percentage points.

The STEP 1 trial extension followed 327 participants for a year after all treatment stopped. Mean weight loss at week 68 was 17.3% with semaglutide; by week 120, participants had regained 11.6 percentage points, leaving a net 5.6% loss from baseline. The authors concluded that the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements.

Every Indication Is Conditioned on Diet and Activity

This is easy to skip and it is written into the labeling. Wegovy is indicated "in combination with a reduced calorie diet and increased physical activity." In the trials, participants received instruction for an approximately 500 kcal/day deficit and physical activity counseling recommending a minimum of 150 minutes per week, beginning with the first dose and continuing throughout.

The reported results are therefore results of a combined intervention. That is not a caveat buried in a footnote; it is the design of the studies that produced the numbers.

The Adverse Reaction Profile Is Predominantly Gastrointestinal

In the pooled adult weight-reduction trials, the Wegovy label reports nausea in 44% of treated patients versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, headache 14% versus 10%, and fatigue 11% versus 5%.

Discontinuation due to adverse reactions occurred in 6.8% of treated patients versus 3.2% on placebo, most commonly for nausea, vomiting and diarrhea. The label carries a boxed warning regarding thyroid C-cell tumors in rodents and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

What This Means for Choosing a Path

The class works, the effect sizes are large by the standards of obesity pharmacotherapy, and the benefit depends on continuation. Those three facts together argue for building a plan you can actually sustain rather than optimizing for the largest number in a trial abstract.

Compounded semaglutide and tirzepatide are a distinct regulatory category from the approved brands: dispensed by a licensed pharmacy against a prescription for an individual patient, and not reviewed by the FDA for safety, effectiveness or quality before marketing. They are not generics, and no approved generic of any of these brands exists.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight did people lose in the semaglutide obesity trials?

In the pivotal 68-week trial reported in the Wegovy prescribing information, adults with obesity or overweight with a comorbidity and without diabetes had a mean body weight change of -14.9% on semaglutide 2.4 mg versus -2.4% on placebo. In that trial, 83.5% lost at least 5% of body weight versus 31.1% on placebo, and 47.9% lost at least 15% versus 4.8%.

Do people regain weight after stopping treatment?

The published evidence indicates yes. In the STEP 1 trial extension, 327 participants were followed for a year after all treatment and lifestyle intervention stopped. Mean weight loss was 17.3% at week 68; participants regained 11.6 percentage points by week 120, leaving a net 5.6% loss. The authors concluded that ongoing treatment appears to be required to maintain improvements.

Is tirzepatide more effective than semaglutide for weight?

The two have not been directly compared in a single obesity trial reported in these labels, so cross-trial comparison is imprecise. SURMOUNT-1 ran 72 weeks in 2,539 adults and reported mean changes of -15.0%, -19.5% and -20.9% versus -3.1% with placebo. The pivotal semaglutide trial ran 68 weeks and reported -14.9% versus -2.4%. Populations and durations differ.

What are the most common side effects?

Predominantly gastrointestinal. The Wegovy label reports nausea in 44% of treated adults versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, and constipation 24% versus 11% in the pooled weight-reduction trials. Adverse reactions led to permanent discontinuation in 6.8% of treated patients versus 3.2% on placebo, most often for nausea, vomiting or diarrhea.

Does diet and exercise still matter on these medications?

Yes, and it is written into the labeled indications, which specify use in combination with a reduced-calorie diet and increased physical activity. In the trials, participants received instruction for an approximately 500 kcal/day deficit and counseling recommending a minimum of 150 minutes per week of physical activity, starting with the first dose. The published results reflect that combined intervention.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.